Capital Group Private Client Services Inc. Acquires 58,335 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital Group Private Client Services Inc. raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 95.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 119,218 shares of the biotechnology company’s stock after acquiring an additional 58,335 shares during the quarter. Capital Group Private Client Services Inc. owned approximately 0.12% of Sarepta Therapeutics worth $14,496,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after buying an additional 117,904 shares during the period. Capital International Investors increased its position in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Geode Capital Management LLC increased its position in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock worth $207,538,000 after acquiring an additional 9,999 shares during the period. Norges Bank bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $126,315,000. Finally, Erste Asset Management GmbH boosted its holdings in shares of Sarepta Therapeutics by 11.3% in the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company’s stock valued at $86,116,000 after purchasing an additional 72,183 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Trading Down 0.3 %

NASDAQ:SRPT opened at $53.79 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a fifty day simple moving average of $82.21 and a 200-day simple moving average of $107.88. Sarepta Therapeutics, Inc. has a 12 month low of $48.01 and a 12 month high of $173.25. The company has a market capitalization of $5.22 billion, a P/E ratio of 43.03 and a beta of 0.93.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft decreased their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Needham & Company LLC cut their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd. Royal Bank of Canada cut shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Finally, Morgan Stanley reduced their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating for the company in a research note on Friday, April 11th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $161.83.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.